Written by Aisha Saleem, Pharmacist & Health Writer at PharmaHealths.com
One of the most common questions I get from patients who’ve just been referred to a dermatologist for biologic treatment is some version of this: “My doctor mentioned a couple of options for psoriasis, and I can’t remember the name, but they sounded similar and ended in ‘-x’.” That’s usually Taltz and Cosentyx, the two most widely used IL-17 inhibitors for psoriasis, and the confusion is understandable.
They work through the same general mechanism, target the same cytokine family, and produce broadly similar results. But the differences between them matter more than people expect. For the right patient, choosing one over the other can shape how quickly results appear, how convenient treatment feels, and how well it fits into daily life.
What Both Drugs Have in Common
Before getting into the differences, it helps to understand what Taltz and Cosentyx share. Both are biologic medications belonging to the IL-17 inhibitor class, meaning both work by blocking interleukin-17A, the cytokine that drives the rapid skin cell turnover and chronic inflammation behind plaque psoriasis.
Both are given as subcutaneous injections, both are approved for moderate to severe plaque psoriasis, psoriatic arthritis, and certain other inflammatory conditions, and both have substantial clinical trial evidence supporting their effectiveness.
According to the National Psoriasis Foundation, IL-17 inhibitors as a class represent some of the most effective targeted treatments available for moderate to severe psoriasis, consistently outperforming older systemic treatments in head-to-head trials.
The Mechanism: Same Target, Slightly Different Approach
Cosentyx (secukinumab) binds directly to IL-17A and neutralizes it before it can interact with its receptor. Taltz (ixekizumab) also targets IL-17A but binds to it with a higher affinity, meaning it attaches more tightly and may block the inflammatory signal more completely.
Research published in the Journal of the American Academy of Dermatology has noted that while both drugs act on the same target, the binding characteristics and pharmacokinetic profiles differ in ways that can translate into meaningful clinical differences, especially in how quickly patients begin to see improvement and how completely plaques clear over time.
Efficacy (How the Trial Data Compares)
Both drugs produce impressive results. The IXORA-S trial, published in the British Journal of Dermatology, directly compared ixekizumab and secukinumab head-to-head and found that ixekizumab achieved statistically higher rates of complete skin clearance at certain time points.
Patients on Taltz were more likely to reach PASI 100, meaning complete clearance of all plaques, particularly at weeks twelve and twenty-four of treatment.
That said, the difference wasn’t dramatic. Secukinumab still produced high rates of near complete clearance, and for many patients the real-world distinction may matter less than individual factors like dosing preference, side effect history, or insurance coverage.
In practical terms, both drugs are highly effective, but if your goal is the highest possible level of skin clearance as quickly as possible, ixekizumab may offer a slight edge.
Dosing (Where the Differences Become More Practical)
This is where Taltz and Cosentyx diverge more noticeably. Cosentyx starts with a loading phase of weekly injections for the first month, then drops to one injection every four weeks for maintenance.
Taltz follows a slightly different schedule: weekly injections for the first month, then injections every two weeks for the next few months, before moving to once every four weeks for long term maintenance.
The more frequent early dosing with Taltz can mean faster initial results for some patients. But it also means committing to more injections early on, which some patients find inconvenient or overwhelming.
Research in The Lancet has pointed to early dosing intensity as a factor that influences both the speed of initial response and the depth of clearance at the end of the induction phase.
Side Effects (A Similar Profile with One Key Difference)
Both drugs share the main safety considerations that come with IL-17 inhibition, including increased susceptibility to fungal infections like oral or skin candidiasis, injection site reactions, and caution around inflammatory bowel disease.
Latent tuberculosis screening is standard before starting either treatment. Serious infections are uncommon, but doctors still monitor closely as a precaution.
Where they differ slightly is in reported rates of injection site reactions. Clinical data reviewed in JAMA Dermatology has noted that ixekizumab tends to have a somewhat higher rate of injection site reactions during the induction phase compared to secukinumab.
These reactions are usually mild, such as redness or burning, and tend to settle as treatment continues, but it’s still something worth knowing ahead of time.
Which One Is Right for You
Patients who want the fastest possible onset and the highest chance of complete clearance may lean toward Taltz based on the head-to-head data.
For example, if you’re preparing for an important event and want quicker visible improvement, this may matter more.
Patients who prioritize a simpler early dosing schedule or who’ve had injection sensitivity with other biologics may find Cosentyx easier to tolerate in the first few months.
If fewer injections early on or better injection comfort is your priority, Cosentyx may feel more manageable.
This decision ultimately belongs with your dermatologist, who can weigh your disease severity, treatment history, coexisting conditions, and insurance coverage.
A Quick Side by Side Summary
Taltz (ixekizumab) tends to show slightly higher rates of complete skin clearance in head-to-head data and has a more intensive early dosing schedule.
Cosentyx (secukinumab) has a somewhat simpler induction phase and a marginally lower rate of injection site reactions.
Both require monthly maintenance injections long term, both carry similar infection and inflammatory bowel disease precautions, and both sit firmly among the most effective targeted treatments available for plaque psoriasis today.
The Bottom Line
If you’re weighing Taltz versus Cosentyx with your dermatologist, go into that conversation knowing you’re choosing between two highly effective options rather than a clear winner and a runner-up.
The better choice is the one that aligns with your goals, whether that’s faster results, fewer injections, or better tolerability, not just what looks slightly stronger on paper.
FAQs
Q1: What is the difference between Taltz and Cosentyx?
Both Taltz (ixekizumab) and Cosentyx (secukinumab) are IL-17 inhibitors that block the same cytokine driving psoriasis. The key differences are that Taltz shows slightly higher rates of complete skin clearance in head-to-head trials, while Cosentyx has a simpler early dosing schedule and a marginally lower rate of injection site reactions.
Q2: Which is more effective, Taltz or Cosentyx?
The IXORA-S trial found that Taltz achieved higher rates of complete plaque clearance at weeks twelve and twenty-four. However, both drugs are highly effective and the difference is modest, the right choice depends on individual factors like dosing preference, treatment history, and insurance coverage.
Q3: How is Taltz dosing different from Cosentyx?
Cosentyx uses weekly injections for the first month, then one injection every four weeks. Taltz also starts with weekly injections, but then moves to every two weeks for several months before settling into monthly maintenance, making the early phase slightly more intensive.
Q4: What are the side effects of Taltz and Cosentyx?
Both carry similar risks including mild fungal infections, injection site reactions, and increased infection susceptibility. Taltz tends to have a higher rate of injection site reactions during the induction phase, while both require tuberculosis screening before starting.
Q5: Can Taltz or Cosentyx cause inflammatory bowel disease?
Both IL-17 inhibitors should be used with caution in patients with existing inflammatory bowel disease, since IL-17 inhibition has been associated with new or worsening IBD symptoms in some patients. Always discuss this with your dermatologist if IBD is a concern.
Q6: How long do Taltz and Cosentyx take to work?
Both drugs begin showing improvement within the first few weeks. Taltz’s more intensive early dosing may produce slightly faster initial clearance for some patients, while full results with both typically build over twelve to sixteen weeks.
Q7: Are Taltz and Cosentyx approved for conditions other than psoriasis?
Yes, both are approved for psoriatic arthritis. Cosentyx is also approved for ankylosing spondylitis. They share the same IL-17 mechanism that makes them effective across related inflammatory conditions.
Q8: How do I choose between Taltz and Cosentyx?
Discuss both options with your dermatologist. Taltz may suit patients prioritizing maximum skin clearance speed, while Cosentyx may work better for those preferring a simpler early dosing schedule or who’ve had injection site sensitivity with other biologics.
Explore More on PharmaHealths
For a deeper look at how IL-17 inhibitors compare to IL-23 inhibitors like Skyrizi, or to understand how Dupixent fits into the eczema side of the picture, explore the full biologics series on PharmaHealths.com.
Disclaimer
This article is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your doctor, dermatologist, or pharmacist before starting, stopping, or changing any treatment.
References
• National Psoriasis Foundation, Overview of biologic treatments and IL-17 inhibitor effectiveness
• Journal of the American Academy of Dermatology, Mechanism and pharmacokinetics of IL-17 inhibitors
• British Journal of Dermatology, IXORA-S head-to-head trial data
• The Lancet, Dosing strategies and treatment response
• JAMA Dermatology, Safety profile and injection site reactions
